Non-Executive Directors - Medicines and Healthcare products Regulatory Agency

Body: Medicines and Healthcare products Regulatory Agency
Appointing Department: Department of Health
Sector: Health
Location: London
Number of Vacancies: 2
Remuneration: £7,883 per annum
Time Requirements: Two to three days per month

Campaign Timeline

  • Competition Launched


  • Closed for Applications

    30/09/2019 at 12:00

  • Panel Sift


  • Final Interview Date


  • Announcement



Assessment Panel

Vacancy Description

Ministers are seeking to make two appointments to the board of the Medicines and Healthcare products Regulatory Agency (MHRA).

As a Non-Executive Director, you will:

  • Provide independent counsel, support and constructive challenge to the Executive.
  • Maintain oversight of the Agency’s operational effectiveness and its relationship with other bodies, including appropriate and constructive relationships with stakeholders.
  • Contribute to the development of the Agency’s strategic objectives, ensuring that they are reflected in its plans and regularly reviewed.
  • Monitor the performance of the Corporate Executive Team, challenging them on the delivery of the Agency’s business and corporate plans.
  • Ensure scrutiny of the Agency’s finances, actively seeking assurance from the Corporate Executive Team on the integrity of financial information and that planning, and accounting are robust and reliable.
  • Bring specific relevant knowledge to support the Agency’s business.

The Department of Health and Social Care values and promotes diversity and encourages applications from all sections of the community. The boards of public bodies should reflect the population they are there to serve. Boards also benefit from fresh perspectives, and we are always keen to encourage candidates from all sections of the community to consider applying for our roles.

Person Specification

To be considered, you must be able to demonstrate that you have the qualities, skills and experience to meet all the essential criteria for appointment.

  • A record of achievement and personal effectiveness at the highest levels, with an ability to operate effectively on the board of a significant national body.
  • Able to provide effective scrutiny and challenge to the Executive and to hold them to account for the delivery of performance and strategy.
  • Excellent communication skills, sound judgement and the highest standards of personal propriety in relation to governance, accountability, risk and financial management.
  • Demonstrable interest in the work of the MHRA and the challenges it faces.

In addition, candidates should bring skills and experience in at least one of the following areas:

Medicine/ Public Health 

  • A medically qualified person, with experience of innovation and public health and the understanding of the value of ‘big data’ and its linkages with public health surveillance and delivery.

Patient/Public engagement

  • A track record of effectively representing the views of patients, service users and/or carers, ensuring the patient voice is heard.

Additional Information

The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices and blood components for transfusion in the UK. It is an executive agency of the Department of Health and Social Care and operates as a government trading fund. The Agency employs more than 1,200 people and has facilities in London, York and South Mimms in Hertfordshire.

Recognised globally as an authority in its field, the agency plays a leading role in protecting and improving public health and supports innovation through scientific research and development.

The agency has three centres:

  • the Clinical Practice Research Datalink (CPRD), a data research service that aims to improve public health by using anonymised NHS clinical data
  • the National Institute for Biological Standards and Control (NIBSC), a global leader in the standardisation and control of biological medicines
  • the Medicines and Healthcare products Regulatory Agency (MHRA), the UK’s regulator of medicines, medical devices and blood components for transfusion, responsible for ensuring their safety, quality and effectiveness

The agency is responsible for:

  • ensuring that medicines, medical devices and blood components for transfusion meet applicable standards of safety, quality and efficacy
  • ensuring that the supply chain for medicines, medical devices and blood components is safe and secure
  • promoting international standardisation and harmonisation to assure the effectiveness and safety of biological medicines
  • helping to educate the public and healthcare professionals about the risks and benefits of medicines, medical devices and blood components, leading to safer and more effective use
  • supporting innovation and research and development that’s beneficial to public health
  • influencing UK, EU and international regulatory frameworks so that they’re risk-proportionate and effective at protecting public health

Role of the MHRA Board:

The MHRA operates a unitary Board, the role of which is to provide strategic advice on the running of the Agency. The Board is collectively responsible for the following:

  • Agreeing the strategic aims and objectives of the Agency, consistent with its overall strategic direction and within the policy and resources framework determined by the Secretary of State;
  • Endorsing the Agency’s recommendations to Ministers on the Agency’s key financial and performance targets and the Agency’s annual business plan and five-year corporate plan;
  • Agreeing the content of the Agency’s annual report to be proposed to the Ministers;
  • Advising on and monitoring:
    • The implementation of strategies to ensure that the regulatory systems for medicines and medical devices are effective and robust, given developments in science and technology, and at an EU and international level;
    • The implementation of strategies for increasing public knowledge and understanding about the safe use of medicines and medical devices
    • The service provided to the manufacturers of medicines and medical devices, to health and social care professionals and to the public
    • The steps taken by the Agency to protect the interests of the public by ensuring that medicines meet appropriate standards of safety, quality and efficacy and that medical devices meet appropriate standards of safety, quality and performance; and
    • The steps taken by the Agency to support innovation and growth and the impact these have had.

The Board ensures that effective arrangements are in place to:

  • Provide assurance and review the controls needed for effective risk management, governance and internal control
  • Demonstrate sound financial management and good value for money
  • Ensure that the Agency has the capability to deliver

The Board is expected to assure itself of the effectiveness of the internal control and risk management systems.

Current priorities:

 Ensure the Agency is best placed to exit the EU and continue to reinforce, and where possible strengthen, the Agency’s global role and regulatory relationships, whatever the outcome of EU Exit.

  • Ensure that the Agency’s seven-year Operational Transformation Programme will deliver a major business transformation to ensure we retain our position as a world-leading regulator using state-of-the-art digital technology.
  • Continue to ensure our regulation is more supportive of innovation and the safe manufacture, sale and supply of medicines and medical devices.
  • Support the government’s growth agenda through the life science strategy and sector deal commitments, which include early access to medicines schemes and the adaptive licensing pilot.
  • Contribute to system wide response to the Independent Medicines & Medical Devices Safety (IMMDS) review, including a fundamental review of our engagement with patients and the public to impact public health and patient safety.
  • Continue to develop our reporting and analysis systems – for adverse incidents with medical devices and adverse drug reactions with medicines – under the established Yellow Card brand to ensure patient safety.
  • Work with our partners across the UK, Europe and globally to prevent counterfeit and substandard products entering the supply chain.
  • Establish a centre of excellence for advanced therapies, including stem cells, at NIBSC.
  • Increase the volume of observational and interventional research, including clinical trials, using CPRD data.
  • Engage and work closely with healthcare professionals, patients and the public, including by working jointly with others in the health and social care system, to increase understanding of medicines and medical devices safety issues and increase the Agency’s impact and influence on clinical practice.

 Useful information:

The Roles

Medicine/ Public Health 

  • A medically qualified person, with experience of innovation and public health and the understanding of the value of ‘big data’ and its linkages with public health surveillance and delivery.
  • The successful candidate will have the opportunity to engage with staff, act as Board sponsors for strands of strategic work, to serve on one of the Board’s sub-committees and on ad-hoc groups.

Patient/Public engagement

  • A track record of effectively representing the views of patients, service users and/or carers, ensuring the patient voice is heard.
  • As a public body, the Agency is keen to meet public and patient expectations of engagement and transparency and have committed to deliver a step-change in the way the Agency conducts its patient and public engagement. This will include how the Agency adopts a more systematic approach to listening to and involving patients – ensuring the patient voice is heard when safety issues are identified and in the licensing of new medicines and medical devices.
  • The successful candidate will have the opportunity to engage with staff, act as Board sponsors for strands of strategic work, to serve on one of the Board’s sub-committees and on ad-hoc groups.

How to Apply

Thank you for your interest in the appointment of a NED to the MHRA.

To make an application please email your CV, a supporting letter and completed monitoring forms to: – please quote VAC:1669 in the subject field.

If you are unable to apply by email you may send your application by post to:

Sally Brough-Hirst Department of Health and Social Care, Room 1N09, Quarry House, Quarry Hill, Leeds, LS2 7UE

Applications must be received by midday on 30 September 2019.

In making an application please note the following:

Supporting letter

The supporting letter is your opportunity to demonstrate how you meet each of the criteria set out in the person specification. It will benefit the Advisory Assessment Panel if you can be clear which specific evidence you provide relates to which criteria. Providing separate paragraphs in relation to each criterion is common practice. Please write all acronyms in full first.

Please ensure your full name, the role to which you are applying and the corresponding reference number for the post are clearly noted at the top of your letter.

Please limit your letter to two pages, and type or write clearly in black ink.

Conflicts of interest

If you have any business or personal interests that might be relevant to the work of the MHRA, and which could lead to a real or perceived conflict of interest if you were to be appointed, please provide details in your Supporting letter.

If appointed, you will also be required to declare these interests on appointment and they will be entered on a register which is available to the public.

Standards in public life and ensuring public confidence

Given the nature of public appointments, it is important that those appointed as members of public bodies maintain the confidence of the public and Government. If there are any issues in your personal or professional history (including any convictions or bankruptcy) that could, if you were appointed, be misconstrued, cause embarrassment to Ministers or the MHRA or cause public confidence in the appointment to be jeopardised, it is important that you bring them to the attention of the Assessment Panel and provide details of the issue/s in your Supporting letter. In considering whether you wish to declare any issues, you should also reflect on any public statements you have made, including through social media and blogs. Due Diligence may be carried out on any publicly available information and shared with the Advisory Assessment Panel.

The panel may explore any issues you declare with you before they make a recommendation on the appointment.

Failure to disclose such information could result in an appointment being terminated, as those who hold public appointments are expected to demonstrate the highest standards of corporate and personal conduct and are required to subscribe to the Code of Conduct for Board Members of Public Bodies, as part of agreeing to the terms and conditions of appointment. You can access this document at:

There are also circumstances in which individuals may not be considered for appointment, due to them not meeting certain eligibility criteria for appointment. For further information, please refer to Section 2.3: Eligibility Criteria

If you wish to discuss any queries on conflicts, please see the contacts section.


Please ensure your CV includes:

  • Your full name, title, home address, personal contact telephone numbers (land line and mobile), personal email address and details of any twitter accounts and LinkedIn accounts including your twitter handle/username.
  • Similar contact details for two referees who will support your application. One referee should be the person to whom you are/were accountable in your current/most recent appointment or position of employment. Please indicate the relationship of each referee to you. References will be requested for short-listed candidates prior to interview
  • Brief details of your current or most recent post and the dates you occupied this role. Please identify any past or present Ministerial appointments.

Monitoring form

Please complete the monitoring form. Diversity monitoring information will not be seen by the Advisory Assessment Panel assessing your application.

Political activity information is primarily for monitoring purposes only, however if you are shortlisted for interview, this information will be shared with the selection panel. The reason for this is that it is appreciated that such activities may have given you relevant skills, including experience gained from committee work, collective decision-making, resolving conflict and public speaking. If you have had such experience and you consider it relevant to your application for this post, you should also take the opportunity to include it separately in your supporting statement. If possible, you should not, however, identify the relevant political party in your statement.

Guaranteed Interview Scheme

The Department of Health and Social Care operates a Guaranteed Interview Scheme (GIS) for disabled people. The Equality Act 2010 defines a person as disabled if they have a physical or mental impairment and the impairment has a substantial and long-term adverse effect on their ability to carry out normal day to day activities. Under the GIS a disabled candidate will be selected for interview if they meet the essential criteria for the post.

If you wish to apply under the GIS please complete the GIS form and return it with your application.

All applications will be acknowledged by email after the closing date.

For further information regarding the selection process, please contact:

Sally Brough-Hirst

Appointments Team

Tel:  0113 2546138


For further information regarding the role of the MHRA and the role of a NED please contact:

Aidan McIvor, Head of Directorate / Office of the Chairman and Chief Executive, MHRA


Please quote reference VAC-1669 on all correspondence.

If you choose to apply, we would like to thank you in advance for your time and effort in making an application.

DHSC diversity & monitoring form (PA)
12.1 DHSC_Privacy-notice-v03
VAC-1669 MHRA NEDs Candidate Information Pack

This post is NOT regulated by The Commissioner for Public Appointments.

Return to Search